OUTCOME OF TREATING PEDIATRIC LANGERHANS HISTIOCYTOSIS WITH LCH III IN TERTIARY CENTER, SAUDI ARABIA
DOI:
https://doi.org/10.47672/ajhmn.667Keywords:
Survival, Pediatric, Langerhans histiocytosis, Multi-system LCH, Single-system LCH.Abstract
Background: Langerhans cell histiocytosis (LCH) is a rare disease affects any age and any organ; its presentations and outcome vary from self-healing lesions to life-threatening disseminated disease. This study evaluated the outcome of treating children diagnosed with Langerhans cell histiocytosis (LCH) at Oncology Center, Saudi Arabia.
Methodology: Through a retrospective study design, the researchers reviewed the medical records and electronic files of all children (aged from 0-≤ 14 years) who had been diagnosed and treated for LCH at Princess Norah Oncology Center (PNOC), King Abdelaziz Medical City, Saudi Arabia, in the period from January 2000 to December 2019 (n=33).
Findings: Males constituted (66.7%), with remarkable dominance of Saudis (93.9%). The median age at diagnosis was 28 months (IQR=49 months); (42.4%) were diagnosed before reaching their second birthday. Fourteen patients (42.4%) had multisystem (MS-LCH) involvement, of which 13 patients with risk organ (RO) (+) and one patient without risk organ (RO) (-). Most of the patients received LCH III protocols. Reactivation occurred in 11 patients (33.3%), and two deaths (6.1%) occurred in cases with MS (RO) (+) progressive disease. The overall survival was 93.9%; with no statistically significant difference in event free survival observed between patients with multisystem compared to single system involvement.
Conclusion and recommendations: Excellent outcome of LCH is associated with single system involvement and worse outcome (reactivations, or morality) is determined by multi-organ involvement especially at younger age less than 24 months. Better understanding of pathophysiology and genetic molecular background could lead to a striking transformation to novel therapy that warrants a prospective clinical trial. A high mortality in patients with progressive disease demands an earlier aggressive salvage in such group. Prospective clinical trials are required for improved treatment strategies in these subgroups
Downloads
References
Abla, O., Egeler, R. M., & Weitzman, S. (2010). Langerhans cell histiocytosis: Current concepts and treatments. Cancer Treatment Reviews, 36(4), 354–359.
Abla, O., & Weitzman, S. (2015). Treatment of Langerhans cell histiocytosis: Role of BRAF/MAPK inhibition. Hematology (United States), 2015, 565–570.
Al-Mulhim, I., Sabbah, R. S., & Al-Akkad, S. (1991). Histiocytosis-X in Saudi children. Indian Journal of Cancer, 28(2), 53–60.
Arico, M., & Egeler, R. M. (1998). Clinical aspects of Langerhans cell histiocytosis. Hematology/Oncology Clinics of North America, 12(2), 247–258.
Azouz, E. M., Saigal, G., Rodriguez, M. M., & Podda, A. (2005). Langerhans’ cell histiocytosis: Pathology, imaging and treatment of skeletal involvement. Pediatric Radiology, 35(2), 103–115.
Belgaumi, A. F., Pathan, G. Q., Siddiqui, K., Ali, A. A., Al-Fawaz, I., Al-Sweedan, S., Ayas, M., & Al-Kofide, A. A. (2019). Incidence, clinical distribution, and patient characteristics of childhood cancer in Saudi Arabia: A population-based analysis. Pediatric Blood and Cancer, 66(6), 53–60.
Broadbent, V., Egeler, R. M., & Nesbit, M. E. (1994). Langerhans cell histiocytosis - clinical and epidemiological aspects. British Journal of Cancer, 33, S11-6.
Cotterill, S. J., Parker, L., Malcolm, A. J., Reid, M., More, L., & Craft, A. W. (2000). Incidence and survival for cancer in children and young adults in the North of England, 1968-1995: A report from the Northern Region Young Persons’ Malignant Disease Registry. British Journal of Cancer, 83(3), 397–403.
Del Río, L., Lassaletta, L., Martínez, R., Sarriá, M. J., & Gavilán, J. (2007). Petrous bone Langerhans cell histiocytosis treated with radiosurgery. Stereotactic and Functional Neurosurgery, 85(2–3), 129–131.
Donadieu, J. (1996). A multicentre retrospective survey of Langerhans’ cell histiocytosis: 348 cases observed between 1983 and 1993. Archives of Disease in Childhood, 75(1), 17–24.
Gadner, H., Grois, N., Arico, M., Broadbent, V., Ceci, A., Jakobson, A., Komp, D., Michaelis, J., Nicholson, S., Pötschger, U., Pritchard, J., & Ladisch, S. (2001). A randomized trial of treatment for multisystem Langerhans’ cell histiocytosis. Journal of Pediatrics, 138(5), 728–734.
Gadner, H., Heitger, A., Grois, N., Gatterer‐Menz, I., & Ladisch, S. (1994). Treatment strategy for disseminated langerhans cell histiocytosis. Medical and Pediatric Oncology, 23(2), 72–80.
Grois, N., Flucher‐Wolfram, B., Heitger, A., Mostbeck, G. H., Hofmann, J., & Gadner, H. (1995). Diabetes insipidus in langerhans cell histiocytosi: Results from the DAL‐HX 83 study. Medical and Pediatric Oncology, 24(4), 248–256.
Grois, Nicole, Fahrner, B., Arceci, R. J., Henter, J. I., McClain, K., Lassmann, H., Nanduri, V., Prosch, H., & Prayer, D. (2010). Central Nervous System Disease in Langerhans Cell Histiocytosis. Journal of Pediatrics, 12(2), 287–305.
Hamre, M., Hedberg, J., Buckley, J., Bhatia, S., Finlay, J., Meadows, A., Nesbit, M., Smithson, A., & Robison, L. (1997). Langerhans cell histiocytosis: An exploratory epidemiologic study of 177 cases. Medical and Pediatric Oncology, 28(2), 92–97.
Histiocyte Society. (2002). Treatment protocol of the Third International Study for Langerhans Cell Histiocytosis. 2nd ed. Viena: Histiocyte Society.
Howarth, D. M., Gilchrist, G. S., Mullan, B. P., Wiseman, G. A., Edmonson, J. H., & Schomberg, P. J. (1999). Langerhans cell histiocytosis diagnosis, natural history, management, and outcome. Cancer, 85(10), 2278–2290.
Kaatsch, P., Haaf, G., & Michaelis, J. (1995). Childhood malignancies in Germany-methods and results of a nationwide registry. European Journal of Cancer, 31a(6), 993–999.
Kilpatrick, S. E., Wenger, D. E., Gilchrist, G. S., Shives, T. C., Wollan, P. C., & Unni, K. K. (1995). Langerhans’ cell histiocytosis (histiocytosis X) of bone a clinicopathologic analysis of 263 pediatric and adult cases. Cancer, 76(12), 2471–2484.
Lahey, M. E. (1975). Histiocytosis X-an analysis of prognostic factors. The Journal of Pediatrics, 87(2), 184–189.
Nezelof, C., & Basset, F. (2004). An Hypothesis Langerhans Cell Histiocytosis: The Failure of the Immune System to Switch from an Innate to an Adaptive Mode. Pediatric Blood and Cancer, 42(5), 398–400.
Salotti, J. A., Nanduri, V., Pearce, M. S., Parker, L., Lynn, R., & Windebank, K. P. (2009). Incidence and clinical features of Langerhans cell histiocytosis in the UK and Ireland. Archives of Disease in Childhood, 94(5), 376–380.
Surico, G., Muggeo, P., Muggeo, V., Conti, V., Novielli, C., Romano, A., Loiacono, G., Ceci, A., & Rigillo, N. (2000). Ear involvement in childhood langerhans’ cell histiocytosis. Head and Neck, 22(1), 42–47.
Titgemeyer, C., Grois, N., Minkov, M., Flucher-Wolfram, B., Gatterer-Menz, I., & Gadner, H. (2001). Pattern and course of single-system disease in langerhans cell histiocytosis data from the DAL-HX 83- and 90-study. Medical and Pediatric Oncology, 37(2), 108–114.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Abrar Salamah Almohammadi, Khalid Abdalla Khalid, Moussa Mohamed Shehadah, Abdullah. A. Baothman
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution (CC-BY) 4.0 License that allows others to share the work with an acknowledgment of the work’s authorship and initial publication in this journal.
